RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

ABSTRACT:

Background

Multiple myeloma (MM) features plasma cell (PC) heterogeneity and alterations in B-cell differentiation and immune regulation. Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear.

Methods

We performed CyTOF profiling on bone marrow samples from RVd- (n = 47) and CyBorD-treated MM patients (n = 15), each compared to untreated cohort (n = 43). Within each therapeutic arm, responders (RVd, n = 35; CyBorD, n = 5) were compared to non-responders (RVd, n = 12; CyBorD, n = 10).

Results

RVd and CyBorD therapies exerted distinct immune modulation patterns, differentially affect

SUBMITTER: Valuskova Z 

PROVIDER: S-EPMC12919894 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature